Similarly to PDGFRα inhibition, inhibition of Gli1 activation by the novel clinically available Shh inhibitor (Shh-I) LDE225[41] restored (P<0.05) and increased (P<0.05) melanoma cells' sensitivity to BRAF-I (Figure 7B). Here, GLI1 is linked to melanoma.